Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Adcentrx Therapeutics starts Phase 1a/b trials of ADRX-0706, a new ADC targeting Nectin-4, for advanced solid tumors
8 October 2023
Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.
Drug Insights
4 min read
Ixekizumab Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Ixekizumab, the Mechanism of Action for Ixekizumab, and the drug target R&D trends for Ixekizumab.
Latest Hotspot
3 min read
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
8 October 2023
Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.
Drug Insights
4 min read
Unleashing the Power of Inclisiran: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Inclisiran, the Mechanism of Action for Inclisiran, and the drug target R&D trends for Inclisiran.
Latest Hotspot
3 min read
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
8 October 2023
A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.
Drug Insights
4 min read
A Comprehensive Review of Heparin sodium's R&D Innovations and Drug Target Mechanism
8 October 2023
This article summarized the latest R&D progress of Heparin sodium, the Mechanism of Action for Heparin sodium, and the drug target R&D trends for Heparin sodium.
Latest Hotspot
3 min read
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
8 October 2023
Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.
Drug Insights
4 min read
Pharmaceutical Insights: Granisetron's R&D Progress and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Granisetron, the Mechanism of Action for Granisetron, and the drug target R&D trends for Granisetron.
Latest Hotspot
3 min read
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
8 October 2023
Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).
Drug Insights
4 min read
Exploring Gliclazide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Gliclazide, the Mechanism of Action for Gliclazide, and the drug target R&D trends for Gliclazide.
Latest Hotspot
4 min read
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
8 October 2023
Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.
Drug Insights
4 min read
Decoding Fosfomycin tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
8 October 2023
This article summarized the latest R&D progress of Fosfomycin tromethamine, the Mechanism of Action for Fosfomycin tromethamine, and the drug target R&D trends for Fosfomycin tromethamine.